

(12) **UK Patent Application** (19) **GB** (11) **2 153 235 A**

(43) Application published 21 Aug 1985

(21) Application No **8502156**

(22) Date of filing **29 Jan 1985**

(30) Priority data

(31) **575091**

(32) **30 Jan 1984**

(33) **US**

(71) Applicant

**Meadox Medicals Inc (USA-New Jersey),
103 Bauer Drive, PO Box 530, Oakland, New Jersey
07436, United States of America**

(72) Inventors

**Harmon Hoffmann
Kemal Schankerell
Milos Chvapil**

(74) Agent and/or Address for Service

**Withers and Rogers,
4 Dyer's Buildings, Holborn, London EC1N 2JT**

(51) INT CL⁴

A61F 2/06 A61K 9/00

(52) Domestic classification

**A5R AR
A5B 805 826 829 832 835 836 839 M
U1S 1036 A5B A5R**

(56) Documents cited

WO 8303536 WO 8203764 US 3272204

(58) Field of search

A5R

(54) **Drug delivery collagen-coated synthetic vascular graft**

(57) A collagen-coated vascular graft includes drug materials complexed with the collagen to be released slowly from the graft following implant, the graft incorporating a tubular porous synthetic vascular graft substrate having a coating of collagen fixed to the graft substrate and cross-linking the collagen *in situ* to render the porous substrate blood-tight. The drug materials complexed with the collagen fibrils may include antithrombic agents, antibacterial, antimicrobial agents, antifungal agents and the like.

GB 2 153 235 A

1/2




FIG. 1







FIG. 2



SPECIFICATION

Drug delivery collagen-coated synthetic vascular graft

5 BACKGROUND OF THE INVENTION 5

This invention relates to a synthetic vascular graft, and more particularly to a drug delivery blood-tight collagen-coated synthetic vascular graft which does not need to be pre-clotted and which acts as a reservoir for sustained release of a drug material after implant.

The replacement of segments of human blood vessels with synthetic vascular grafts is well 10 accepted in the art. Synthetic vascular grafts have taken a wide variety of configurations and are formed of a wide variety of materials. Among the accepted and successful vascular graft implants are those which are formed from a biologically compatible material which retains an open lumen to permit blood to flow through the synthetic graft after implant. The grafts may be made from biologically compatible fibers, such as Dacron and Teflon, may be knitted or woven 15 and may be of a mono-filament yarn, multi-filament yarn or staple yarn. 15

An important factor in the selection of a particular graft substrate is the porosity of the fabric wall of which the graft is formed. Porosity is significant because it controls the tendency to hemorrhage during and after implantation and controls the ingrowth of tissue into the wall of the graft. It is desirable that the vascular graft substrate be sufficiently blood-tight to prevent the 20 lost of blood during implant, yet the structure must be sufficiently porous to permit ingrowth of fibroblast and smooth muscle cells in order to attach the graft to the host tissue. Synthetic vascular grafts of the type described in United States Patents No. 3,805,301 and No. 4,047,252, assigned to the assignee of the subject application, are elongated flexible tubular bodies formed of a yarn such as Dacron. In the earlier patent, the graft is a warp knitted tube 25 and in the latter issued patent it is a double-velour synthetic graft marketed under the trademark Microvel. These types of grafts have sufficiently porous structures to permit ingrowth of host tissue. 25

The general procedure for implantation includes the step of pre-clotting, wherein the graft is immersed in the blood of the patient and allowed to stand for a period of time sufficient for 30 clotting to insure. After pre-clotting, hemorrhaging does not occur when the graft is implanted and growth of tissue is not impeded. Graft infection is a most serious complication and occurs in an average of two percent of prosthetic graft placements. It is associated with a high risk of limb loss and patient mortality is as high as 75% depending on the location of the graft. While infection usually becomes evident soon after surgery, the time may be extended which leads to 35 more serious consequences. 35

An absorbable collagen reinforced graft is proposed in United States Patent No. 3,272,204 wherein the collagen is obtained from the deep flexor tendon of cattle. Another reinforced vascular prosthesis is described in United States Patent No. 3,479,670 which includes an open mesh cylindrical tube wrapped by an outer helical wrapping of fused polypropylene mono- 40 filament filled with collagen fibrils which are claimed to render the prosthesis impermeable to bacteria and fluids. The collagen fibrils utilized are the same as described in Patent No. 3,272,204. 40

The synthetic vascular grafts suggested by the prior art are claimed to be suitable for many applications. However, it is desirable to provide a flexible vascular graft having zero porosity, 45 one which is receptive to ingrowth of host tissue and serves as a reservoir for drug materials to be released slowly from the surface of the graft following implant. 45

SUMMARY OF THE INVENTION

A collagen coated synthetic vascular graft which provides a reservoir for the slow release of a 50 drug material after implant is provided. The collagen fibrils in the coating are complexed with a drug material such as antibacterial agents, antithrombic agents and antiviral agents to insure against graft infection. 50

The porous graft substrate may be a tubular vascular graft formed of a Dacron material and may be woven or knit. The collagen source is an aqueous fibril dispersion of high purity 55 including a plasticizer and is applied to the graft substrate by massage to cover at least the entire inner surface area to provide a flexible graft with good hand. After repeated coating and drying applications, the collagen is cross-linked by exposure to formaldehyde vapor. 55

Accordingly, it is an object of the invention to provide an improved synthetic vascular graft.

Another object of the invention is to provide an improved collagen-coated synthetic vascular 60 graft. 60

A further object of the invention is to provide an improved collagen-coated synthetic vascular graft wherein the collagen serves as a reservoir for the slow release of a drug after implantation.

Still another object of the invention is to provide an improved process for coating a synthetic vascular graft with collagen to render the graft blood-tight and serve as a reservoir for the slow 65 release of a drug after implantation. 65

Still other objects and advantages of the invention will in part be obvious and will in part be apparent from the specification.

The invention accordingly comprises the article possessing the features, properties and the relation of elements and the several steps and the relation of one or more of such steps with respect to each of the others, which are exemplified in the following detailed disclosure, and the scope of the invention will be indicated in the claims.

BRIEF DESCRIPTION OF THE DRAWING

For a fuller understanding of the invention, reference is had to the following description taken in connection with the accompanying drawing, in which:

Figure 1 is a partial cross-sectional view of a collagen-coated synthetic vascular graft in accordance with the invention;

Figure 2 is a partial cross-sectional view of a branched tubular graft of the type illustrated in Fig. 1;

Figure 3 is a graph illustrating sustained release of tetracycline from a collagen slurry in rabbits;

Figure 4 is a graph illustrating sustained release of tetracycline at different collagen gel concentrations; and

Figure 5 is a graph illustrating sustained release of tetracycline in a collagen gel at different concentrations and dosage.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

A synthetic vascular graft 10 constructed and arranged in accordance with the invention is shown in Fig. 1. Graft 10 includes a tubular substrate portion 12 which is formed of a biologically compatible filamentary synthetic material, preferably a polyethylene terephthalate, such as Dacron. Substrate 12 is a porous Dacron warp knit fabric having an inner and outer velour surface of the type described in U.S. Patent 4,047,252. While tubular portion 12 is formed of Dacron, any biocompatible filamentary material may be used for the substrate provided it may be fabricated into a porous structure which will permit tissue ingrowth and maintain an open lumen for flow of blood.

The inner surface of tubular portion 12 is coated with a collagen coating shown as 16. Collagen coating 16 is formed from a series of at least three layers of applied collagen fibrils. Fig. 2 shows a bifurcated collagen-coated graft 20. Graft 20 includes a main tubular portion 22 and two branches 24. Main tubular portion 22 and bifurcated portions 24 are formed from a Dacron knit substrate 26. The inner surface coating of substrate 26 is coated with a collagen coating 28 also formed of at least three layers of collagen fibrils.

Porous vascular graft substrates suitable for use in accordance with the invention, preferably are produced from Dacron multi-filament yarns by knitting or weaving processes which are commonly used in manufacture of these products. Generally, the porosity of the Dacron substrate ranges from about 2,000 to 3,000 ml/min-cm² (purified water at 120mm Hg). The inner coating of cross-linked collagen is applied by filling a tubular substrate with a slurry of collagen fibrils and plasticizer and massaging manually, removing the excess and permitting the deposited dispersion to dry. After the final application, the collagen coating is cross-linked by exposure to formaldehyde vapor, air dried and then vacuum dried to remove excess moisture and excess formaldehyde. The coated grafts in accordance with the invention have essentially zero porosity.

The following examples are set forth to illustrate the method of preparing purified collagen from bovine skin and coated grafts in accordance with the invention. The examples are set forth for purposes of illustration and not intended in a limiting sense.

Example 1

Fresh calf skins were mechanically stripped from young calves, fetuses or stillborns and washed in a rotating vessel with cold running water until the water was observed to be free from surface dirt, blood and/or tissues. The subcutis was mechanically cleaned to remove contaminating tissues, such as fat and blood vessels. Subsequently, the skins were cut in the longitudinal direction into strips about 12 cm wide and were placed in a wood or plastic vessel as commonly used in the leather industry.

The skins were dehaired by using a flush solution of 1 M Ca(OH)₂ for 25 hours. Alternatively, the skin may be dehaired by mechanical means or by a combination of chemical and mechanical means. Following the dehairing, the skins were cut into small size pieces about 1" x 1" and were washed in cold water.

Following washing, 120 Kg of the bovine skin was placed in a vessel having 260 L water, 2 L NaOH (50%) and 0.4 L H₂O₂ (35%). The components were mixed slowly for 12 to 15 hours at 4°C and washed with an excess of tap water for 30 minutes to provide partially purified skins. The partially purified skins were treated in a solution of 260 L water, 1.2 L NaOH (50%)

and 1.4 Kg CaO for 5 minutes with slow mixing. This treatment was continued twice daily for 25 days. Following this treatment, the solution was discarded and the skins were washed with an excess of tap water for 90 minutes under constant stirring.

- The skins were acidified by treatment with 14 kg HCl (35%) and 70 L water while subjecting the skins to vigorous stirring. The acid was allowed to penetrate the skins for about 6 hours. Following acidification, the skins were washed in an excess of tap water for about 4 hours or until a pH of 5.0 was reached. The pH of the skins was readjusted to 3.3–3.4 using acetic acid with a 0.5% preservative. The purified skin was then passed through a meat grinder and extruded under pressure through a series of filter sieves of constantly decreasing mesh size. The final product was a white homogeneous smooth paste of pure bovine skin-derived collagen. In order to impart adequate pliability to the grafts in the dry state, plasticizers are added to the collagen slurry before application. Suitable plasticizers include glycerine, sorbitol or other biologically acceptable plasticizers. In a collagen slurry containing between about 0.5 to 5.0 percent collagen by weight, the plasticizer is present in an amount between about 4 and 12 weight percent.

- Among the most important properties obtained when coating a synthetic vascular graft with collagen fibrils in accordance with the invention is reduction of porosity of the porous substrate to about zero. The porosity of twenty randomly selected uncoated Microvel Dacron synthetic vascular grafts have a mean porosity to purified water of 1796 ml/min-cm² at 120 mm Hg with a standard deviation of 130. After applying several collagen coatings, the porosity is reduced to zero. The following example illustrates the method of coating the graft substrate.

Example 2

- A 50 cc syringe is filled with an aqueous slurry of 2% purified bovine skin collagen prepared in accordance with Example 1. The collagen slurry includes 8% glycerol, 17% ethanol and the remainder water and a viscosity of 30,000 cps. The syringe is placed into one end of a Meadox Medical Microvel Dacron graft 8 mm in diameter by approximately 12 cm in length. The slurry is injected into the lumen of the Microvel graft and it is massaged manually in order to cover the entire inner surface area with the collagen slurry. Any excess collagen slurry is removed through one of the open ends. The graft is permitted to dry for about 1/2 hour at room temperature. The coating and drying steps were repeated three more times.

- Following the fourth coating application, the collagen coating was cross-linked by exposure to formaldehyde vapor for 5 minutes. The cross-linked graft was then air dried for 15 minutes and then vacuum dried for 24 hours to remove moisture and any excess formaldehyde.

Example 3

- The blood-tightness of a collagen-coated vascular graft prepared in accordance with Example 2 was tested as follows. A Microvel graft 8 mm × 12 cm was attached to a blood reservoir at a pressure of 120 mm Hg due to the height of the reservoir. Heparin stabilized blood was passed through the graft and blood collected through the grafts was determined and expressed in ml per min-cm². The porosity over 5 runs was determined to be 0.04, 0.0, 0.0, 0.04 and 0.03. This represents a mean porosity of 0.022 ml/min-cm² which was considered zero, as the value is within the experimental error of the study.

- In order to compare this result with the blood loss for uncoated Microvel graft, the experiment was repeated using an uncoated graft. The mean porosity was 36 ml/min-cm².

The antimicrobial activity of a collagen coated fabric graft prepared in accordance with the invention is demonstrated as follows.

Example 4

- The porosity of a collagen fabric graft is reduced to less than about 1 percent of an uncoated graft after three coatings. A standard water porosity test used to measure water porosity of a graft is as follows. A column of water equivalent to 120 mm Hg pressure is allowed to flow through a one-half cm² orifice having a sample of graft over the orifice for one minute. The amount of water collected was measured. The milliliters of water collected per minute per cm² squared area was calculated. Several readings are taken for each sample. The porosity is reported as follows:

$$\text{porosity} = \text{ml/min/cm}^2$$

The water porosity of a Microvel graft fabric was about 1,900 ml/min/cm². The porosity after coating was as follows:

	Number of Coatings	Porosity	
5	0	1,900	5
	1	266	
	2	146	
	3	14	
	4	5	
10	5	2.2	10
	6	0	

In each case the collagen coating was a bovine skin derived-plasticized slurry prepared in accordance with the composition described in Example 2. Based on these results, it is preferable to provide a collagen coating of at least three of four layers of fibrils, and most preferably four or five layers with drying between each application and cross-linking to fix the coating to the substrate.

In accordance with the invention, each layer of the collagen coating and at least the last two layers applied to a porous substrate are chemically modified to incorporate a drug or an antithrombic agent, such as heparin, in order to prevent infection and to inhibit clotting along the inner surface of the prosthesis. As noted, the collagen may be complexed with a variety of drugs, such as antibacterial agents, antimicrobial agents or antifungal agents in order to prevent graft infection. Typical antibacterial agents which may be utilized include oxacillin, gentamicin, tetracycline, cephalosporin and the like which may be complexed with the collagen fibrils prior to application to the graft substrate.

In addition to reduced porosity, collagen coated vascular grafts in accordance with the invention exhibit reduced thrombogenicity compared to uncoated grafts.

Example 5

A homogeneous slurry of bovine skin derived collagen prepared in accordance with Example 1 was prepared containing 1% bovine skin derived collagen, 8% glycerol, 17% ethanol with the remainder water. Ceclor, a cephalosporin antibiotic of Eli Lilly and Company which inhibits the growth of *Staphylococcus aureus* and *Escherichia coli*, was blended into the slurry at a concentration of 20 mg per ml. The collagen slurry including the Ceclor was massaged coated onto a double velour Dacron fabric on both sides with 1/2 hour drying periods between coats. The coating resulted in the addition of 3.1 mg collagen per cm².

As a control, Dacron double velour fabric was also impregnated with the same collagen slurry omitting the Ceclor antibiotic. This control had a coating of 4.1 mg of collagen per cm².

Both pieces of coated fabric were immersed for 1 minute in 4% formaldehyde, 10% glycerol solution, vacuum desiccated for 64 hours and sterilized using gamma radiation.

The antimicrobial activity of the collagen coated Dacron vascular graft fabric, impregnated with Ceclor, was determined in an agar diffusion assay. Fabric swatches of 1 cm² were placed on inoculated agar surface resulting in growth inhibition zones which indicated that the antibiotic was active against *S. aureus* (34 mm zone of inhibition) and *E. coli* (29 mm zone of inhibition). The untreated control collagen coated vascular graft fabric did not exhibit any antimicrobial effect. The results are tabulated in the following Tables I and II.

TABLE I

TREATED COLLAGEN COATED FABRIC

	PLATE 1	PLATE 2	PLATE 3	x ₃	
<i>S. aureus</i>	36mm	31mm	35mm	34mm	
<i>E. coli</i>	33mm	28mm	27mm	29mm	

TABLE II
UNTREATED COLLAGEN COATED FABRIC

5		PLATE 1	PLATE 2	PLATE 3	x_3	5
	<i>S. aureus</i>	0	0	0	0	
	<i>E. coli</i>	0	0	0	0	

10 5

Example 6

A collagen slurry prepared in accordance with Example 1 containing 13.2% collagen protein (determined by its hydroxyproline content) was mixed in a 1:3 ratio with water (W) to form a 3.3 weight percent homogeneous collagen gel (G). The pH of the collagen gel was adjusted to 3.8 and 20mg of tetracycline (TC) was added per millimeter of gel. Immediately before injection into two rabbits, the collagen gel-tetracycline complex was mixed with glutaraldehyde (0.3 ml of 3% glutaraldehyde per ml of the gel) and injected through 18 gage needles into the subcutis. Two rabbits as controls were injected with a similar dose of tetracycline and water, 20 mg TC/ml water/kg body weight.

In order to study the rate of tetracycline released from the injected site, blood was collected at various time intervals from the rabbit's ear vein. The content of TC in the blood was measured according to the procedure of Wilson, et al. (Clin. Chem. Acta., 36; 260, 1972). The results of the TC analysis in the blood of the total of four rabbits collected within 2 hours to 7 days post-injection are set forth in Fig. 3.

Fig. 3 shows that after injection of TC in water the drug reaches its maximum in the serum within two hours as shown by Curve A. At 11 hours the TC is no longer detectable. When tetracycline was administered in a collagen gel cross-linked with glutaraldehyde (10G + 30W), the level of serum TC remained stable for about 6 days as shown by Curve B. Thus, administration of TC in collagen gel prolonged the effective release of the drug 25 times compared with injection in an aqueous medium only.

Example 7

The test described in Example 5 was repeated using collagen gel at two different concentrations for the final injection. Additionally, the tetracycline content was 30 mg oxytetracycline (OTC)/ml gel/kg body weight at a dose of 1 ml/kg of body weight, or 50% more tetracycline per dose than Example 5. The results illustrated in Fig. 4 show that the concentration of collagen in the gel affects the rate of OTC release from the collagen matrix. The denser the collagen gel, the slower is the release of the drug. In this Example, the kinetics of the OTC release was studied for a total of 124 hours after injection of the tested complex in the subcutis of a total of six rabbits.

In Fig. 4 Curve A shows that the OTC in water reaches its maximum in the serum shortly after injection and is not detectable after 18 or 20 hours. Curve B shows OTC serum concentration for OTC complexed with a collagen matrix at a weight ratio of gel complex to water of 1:20 and Curve C at 3:20. Release of the OTC is more rapid for the less concentrated gel of Curve B.

Example 8

Collagen gel containing 3% collagen, measured as a dry substance, was mixed with tetracycline to form two concentrations, containing (A) 50mg TC/ml and (B) 100mg TC/ml gel. After mixing with 0.3 ml of 3% glutaraldehyde (G1) per ml gel (G), complex A was injected at a dosage of 2 ml/kg body weight and complex B was injected at a dosage of 1 ml/kg. Plasma level concentrations of TC in mg/ml are shown in Curves A and B of Fig. 5. Complex A was also injected at a dosage of 1 ml/kg and is shown by Curve C in Fig. 5. The actual plasma levels of tetracycline during the period up to 5 days post-injection are shown in Fig. 5.

The data of Fig. 5 show that both the actual concentration of tetracycline as well as the surface geometry of the implant affects the level of magnitude of drug release from the gel and the level of tetracycline in the plasma.

It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained and, since certain changes may be made in the article and in carrying out the above process without departing from the spirit and scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.

Particularly it is to be understood that in said claims, ingredients or compounds recited in the singular are intended to include compatible mixtures of such ingredients wherever the sense permits.

5

5

CLAIMS

1. A synthetic vascular graft comprising:
a tubular flexible porous graft substrate;
the graft substrate having on at least the inner surface a cross-linked coating of collagen fibrils
10 complexed with an effective amount of a drug and admixed with a plasticizer for rendering the
graft blood-tight and flexible and providing for sustained release of the drug portion of the
complex after implantation.
2. The vascular graft of claim 1, wherein the drug portion of the complex is a pharmaceuti-
15 cal agent selected from the group consisting of antimicrobial agents, antibacterial agents, anti-
fungal agents, antithrombogenic agents, cell-proliferation promoting agents and mixtures
thereof.
3. The vascular graft of claim 1, wherein both inner and outer surfaces of the graft are
coated with the collagen fibril-drug complex.
4. The vascular graft of claim 1, wherein the coating of the collagen fibril-drug complex is at
20 least three layers formed by depositing an aqueous slurry of collagen fibrils which have been
dried between applications and cross-linked after application of the last layer.
5. The vascular graft of claim 1, wherein the porous substrate is polyethylene terephthalate.
6. The vascular graft of claim 5, wherein the porous substrate is knitted.
7. The vascular graft of claim 5, wherein the porous substrate is woven.
- 25 8. The vascular graft of claim 5, wherein the inner and outer surface of the substrate have a
velour surface.
9. The vascular graft of claim 1, wherein the collagen fibrils-drug complex are cross-linked
by exposure to formaldehyde vapor.
10. The vascular graft of claim 1, wherein the plasticizer is a biologically compatible
30 polyhydric material.
11. The vascular graft of claim 10, wherein the plasticizer is sorbitol.
12. The vascular graft of claim 10, wherein the plasticizer is glycerine.
13. A process for preparing a drug delivery collagen-coated synthetic vascular graft,
comprising:
35 providing a porous tubular flexible synthetic graft substrate;
placing an aqueous slurry of a complex of collagen fibrils complexed with a drug onto the
surface of the substrate;
massaging the slurry into the substrate to insure intimate mixing of the collagen fibril complex
into the porous structure of the substrate;
40 drying the collagen coating;
cross-linking the collagen coating by exposure to formaldehyde vapor; and
vacuum drying to remove excess formaldehyde.
14. The process of claim 13, wherein the steps of placing an aqueous slurry of collagen
fibrils onto the substrate, massaging and drying is repeated at least three times.
- 45 15. A slurry for forming a drug delivery blood-tight synthetic vascular graft comprising about
0.5 to 5.9 percent collagen fibrils complexed with at least an effective amount of a drug
material, 4.0 to 12.0 percent plasticizer and the balance water.
16. A synthetic vascular graft comprising:
a tubular flexible porous polyethylene terephthalate graft substrate;
50 the inner surface having a coating of at least five layers of cross-linked collagen fibrils
complexed with a drug and admixed with a plasticizer;
each layer formed from an aqueous slurry containing between about 1.5 to 4.0 weight
percent collagen fibrils and between about 6 and 10 weight percent plasticizer.